TPG Makes Strategic Investment in SCHOTT Poonawalla

Chennai: TPG, a leading global alternative asset management firm, has entered into a binding agreement to acquire a 35% stake in SCHOTT Poonawalla, a joint venture between SCHOTT Pharma and Serum Institute of India (SII). The investment will support SCHOTT Poonawalla’s growth and global ambitions.

The partnership brings together TPG’s healthcare investing experience and local expertise in India with SCHOTT Pharma’s innovation capabilities and SII’s expertise in vaccine manufacturing. SCHOTT Poonawalla will continue to design advanced drug containment and delivery solutions for pharmaceutical and biotechnology customers.

Quotes from Partners

• Bhushan Bopardikar, Business Unit Partner at TPG Growth: “We are excited to partner with SCHOTT Pharma and Serum Institute of India and build upon SCHOTT Poonawalla’s market leadership position.”
• Adar Poonawalla, CEO of Serum Institute of India: “Partnering with TPG marks an important step for us, and their experience in healthcare investing and global network make them a strong partner.”
• Andreas Reisse, CEO at SCHOTT Pharma: “Welcoming TPG to the partnership marks an exciting step forward in our collaboration and will further enhance our global footprint.”
• Ashok Saxena, Managing Director, SCHOTT Poonawalla: “We are excited to welcome TPG onboard as an investor, and are confident that their proven track record will greatly benefit SCHOTT Poonawalla.”